Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

The Prostate Project kicks of 2016 OctoBeardFest campaign

Aims to raise awareness and funds for prostate cancer research

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

- PMLiVE

Lucid Group becomes a sponsor of MedComms Networking

To help Lucid access the valuable medical communications professional network they have become a sponsor of MedComms Networking, headed by Peter Llewellyn. Jan Steele (Co-founder and COO of Lucid Group)...

Lucid Group Communications Limited

- PMLiVE

Market access improvements in Turkey

With 78 million inhabitants, a universal public health insurance scheme, regulations largely harmonised with EU rules and a growing economy, Turkey - the largest market in the Middle East, North...

EMD Serono appoints neurology and immunology SVP

Promotes head of US Fertility and Endocrinology Craig Millian

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

Showcasing our multichannel capabilities in Berlin

Join Anthill for conferences in October to understand how to bring value to HCPs through multichannel communications

Anthill Agency

- PMLiVE

XenoGesis appoints business development consultant

Sabrina Mogle will spearhead CRO’s US growth

- PMLiVE

AZ withdraws EU filing for ovarian cancer drug cediranib

Maintains cediranib’s value as a combination therapy despite EMA information request

- PMLiVE

Key Accounts

But not as we know it?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links